Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Treasury Shares (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Treasury Shares for 4 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares changed N/A to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.2 million for FY2025, N/A changed from the prior year.
  • Treasury Shares for Q4 2025 was $2.2 million at Phathom Pharmaceuticals, up from $19.0 in the prior quarter.
  • The five-year high for Treasury Shares was $2.6 million in Q2 2025, with the low at $19.0 in Q2 2022.
  • Average Treasury Shares over 4 years is $539472.7, with a median of $15931.5 recorded in 2022.
  • The sharpest move saw Treasury Shares tumbled 99.99% in 2023, then changed 0.0% in 2025.
  • Over 4 years, Treasury Shares stood at $254437.0 in 2022, then crashed by 99.99% to $19.0 in 2023, then changed by 0.0% to $19.0 in 2024, then skyrocketed by 11339815.79% to $2.2 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $2.2 million, $19.0, and $2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.